Protagonist Therapeutics, Inc. PTGX 深 滬
等待開盤 05-13 09:30:00 美东时间
100.815
-2.685
-2.59%
華盛通- 最 高103.50
- 今 開103.50
- 成交量 26.50万股
- 最 低 100.27
- 昨 收 103.50
- 總市值 64.84亿
- 52周最高 107.84
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 45.28
- 委 比 86.89%
- 總股本 6431.14万
- 歷史最高 107.84
- 量 比 0.92
- 振 幅 3.12%
- 歷史最低 4.47
- 每 手 1
- 風險率 18.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.
05-06 20:48
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q1营收0.56亿美元，同比增长99.0%；归母净利润0.04亿美元，扭亏为盈
华盛资讯5月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q1业绩，公司Q1营收0.56亿美元，同比增长99.0%，归母净利润0.04亿美元，扭亏为盈。
05-06 06:20
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over losses of $(0.19) per
05-06 04:39
Protagonist Therapeutics Exercises Opt-Out Of Rusfertide 50:50 Profit And Loss Sharing Arrangement With Takeda, Eligible For Up To $400M In Opt-Out Payments
By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the opt-out election and a
04-28 21:11
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $121
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $110 to $121.
04-15 23:22
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
04-07 21:10
Clear Street Maintains Buy on Protagonist Therapeutics, Raises Price Target to $116
Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $104 to $116.
04-07 18:10
